Cinclus Pharma Holding AB (FRA:J8P) Total Operating Expense: €28.48 Mil (TTM As of Mar. 2026)


FRA:J8P Cinclus Pharma Holding AB FRA:J8P
4 GF Score
Price €1.03
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB Total Operating Expense?

Cinclus Pharma Holding AB FRA:J8P +0.39% 4 Total Operating Expense is €28.48 Mil as of Mar. 2026. GuruFocus rates FRA:J8P with a GF Score™ of 4/100. The stock has 3 warning signs investors should review.

Cinclus Pharma Holding AB's Total Operating Expense for the three months ended in Mar. 2026 was €9.37 Mil. Cinclus Pharma Holding AB's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €28.48 Mil.

Cinclus Pharma Holding AB Total Operating Expense Related Terms

Cinclus Pharma Holding AB Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Cinclus Pharma Holding AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cinclus Pharma Holding AB Total Operating Expense Chart

Cinclus Pharma Holding AB Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
8.21 20.13 18.44 15.08 23.49

Cinclus Pharma Holding AB Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.34 7.26 4.90 6.95 9.37
FRA:J8P
4GF Score
Cinclus Pharma Holding AB FRA:J8P
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €28.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €28.48 Mil mean?
Cinclus Pharma Holding AB (FRA:J8P) has a Total Operating Expense of €28.48 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Cinclus Pharma Holding AB and its competitors.
Is Cinclus Pharma Holding AB's Total Operating Expense too high?
Cinclus Pharma Holding AB's current Total Operating Expense is €28.48 Mil. Overall, Cinclus Pharma Holding AB has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Total Operating Expense compare to ZTS and UTHR?
Cinclus Pharma Holding AB's Total Operating Expense of €28.48 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Cinclus Pharma Holding AB and its competitors. Cinclus Pharma Holding AB's current Total Operating Expense is €28.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current Total Operating Expense of €28.48 Mil. The current Total Operating Expense is €28.48 Mil. Cinclus Pharma Holding AB's overall GF Score™ is 4/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current Total Operating Expense is €28.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cinclus Pharma Holding AB Business Description

Other Exchanges CINPHA:Sweden
Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
4GF Score

Get the complete analysis for FRA:J8P

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.03
Price